Black showed that blocking β-receptors or H2-receptors lets a drug act on a chosen organ only. Elion and Hitchings mapped purine and pyrimidine pathways and created “antimetabolites” that shut down enzymes vital to cancer cells or viruses. Their work established the idea that medicines can be both powerful and gentle, a principle that underlies modern drug development.

Black introduced the receptor-antagonist concept and, through the development of propranolol (β-blocker) and cimetidine (H2-blocker), proved that target selectivity reconciles efficacy with safety. Elion and Hitchings designed purine analogues that systematically inhibit enzymes in nucleotide biosynthesis, yielding drugs such as 6-mercaptopurine, azathioprine, and acyclovir. Their strategy evolved into structure-activity relationships, lead optimization, and combinatorial chemistry, transforming drug discovery into a rational, hypothesis-driven enterprise.

Black quantified the relationship between receptor occupancy and pharmacodynamic response, linking functional antagonism theory with clinical efficacy via β-AR and H2R antagonists. Elion and Hitchings validated inhibition of the purine de novo pathway in human leukemia models and demonstrated virus-selective activation with acyclovir through HSV-TK specificity. Their work foreshadowed target-based discovery, pro-drug strategies, and immunosuppressive therapy paradigms, providing a foundation for contemporary molecularly targeted drug design.